24 okt: Schering: Undersøgelsesresultat vedr. tidlig MS offentlig...
24 okt: Fabricius og Kastholms møbelklassikere
24-10-2006 11:39:00

Hugin Ad hoc announcement according to § 15 WpHG: Misc. business figure: STRATEC Biomedical Systems AG: STRATEC clearly exceeds earnings for overall previous year after only nine months

Birkenfeld, October 24, 2006

The Board of Management of STRATEC Biomedical Systems AG, which is

listed in the Prime Standard and Gate-M indices, hereby announces the

preliminary, unaudited consolidated figures based on IFRS

(International Financial Reporting Standards) of the STRATEC Group

for the first nine months of the 2006 financial year pursuant to

Section 15 of the German Securities Trading Act (WpHG).

+-------------------------------------------------------------------+

| Key Figures (EUR | 01.01.- | 01.01.- | Change |

| 000s) | 09.30.2006 | 09.30.2005 | |

|---------------------+-----------------+-----------------+---------|

| Sales | 51,933 | 33,945 | + 53.0% |

|---------------------+-----------------+-----------------+---------|

| Gross performance | 51,887 | 35,582 | + 45.8% |

|---------------------+-----------------+-----------------+---------|

| EBITDA | 8,295 | 5,315 | + 56.1% |

|---------------------+-----------------+-----------------+---------|

| EBIT | 7,199 | 4,587 | + 56.9% |

|---------------------+-----------------+-----------------+---------|

| EBT | 7,097 | 4,409 | + 61.0% |

|---------------------+-----------------+-----------------+---------|

| Consolidated net | 5,304 | 2,895 | + 83.2% |

| income | | | |

|---------------------+-----------------+-----------------+---------|

| Earnings per share | 0.48 | 0.29 | + 65.5% |

| (EUR) | | | |

+-------------------------------------------------------------------+

The STRATEC Group had a total of 215 employees as of

September 30, 2006 (previous year: 189).

Information and disclosures concerning this ad-hoc announcement:

Irrespective of possible new levels of sales and earnings correlating

with the market launch of new analyzer system families, the company

assumes that the seasonal fluctuations witnessed in sales and

earnings in the past will be increasingly countered by logistical

measures involving procurement and production.

In the past 2005 financial year, the STRATEC Group had an average of

191 employees and generated sales of Euro 47.3 million, earnings

before tax (EBT) of Euro 6.9 million and consolidated income of Euro

4.4 million, with earnings per share of Euro 0.43 (earnings for

overall previous year).

The extensive interim report will be available on our internet page

as a download from around 3 p.m. on November 8, 2006.

Based on current budgeting, the growth forecast for the company will

be reflected in particular from the second and third quarter of the

2007 financial year onwards.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Ad-hoc Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 okt
VWS
Fra tid til anden lytter jeg til Solveig Bjørnestad’s P1 Business. Hun er dygtig til at lave en 360 ..
36
27 okt
VWS
Normal 0 21 false false false DA X-NONE X-NONE ..
26
26 okt
BAVA
Jeg synes du skulle lade være med at bekymre dig om kortsigtede udsving, og ganske enkelt gå lang i ..
16
28 okt
I:SP500
Det ser grundlæggende ganske fint ud makroøkonomisk, hvilket ikke er det samme som at der ikke finde..
15
28 okt
VWS
 Fredag d. 3. okt. i år var den norske Olie- og energiminister Tord Lien og næstformand for det nors..
14
29 okt
VWS
Hej Pokerchamp, det du kalder 'amatør-detektiv'-arbejde er langt mere informativt end dine ukonstruk..
12
23 okt
VWS
Quantum Utility Generation er på den anden side af "Mountain Friends", og de kan nu fortsætte deres ..
12
16:22
DANSKE
Og pludselig savner jeg alligevel den der "røde tommel ned"  der endgang var her på EI 
11
29 okt
FING-B
Swift - det er jo fuldkommen ligegyldigt hvad vi siger eller gør så synes du og dit slæng det er for..
11
26 okt
 
Læg mærke til medierne altid fokuserer på de dårlige nyheder! Verden er af lava og vi hører konstant..
11

Schouw/CEO: Har flere opkøb i kikkerten

30-10-2014 15:39:25
Industrikonglomeratet Schouw & Co. har appetit på yderligere opkøb til sine porteføljevirksomheder.Det siger selskabets administrerende direktør Jens Bjerg Søre..

Novo/S&P Capital: Hæver kursmål til 273 kr. fra 253 kr.

30-10-2014 13:03:29
Analytikerne hos S&P Capital IQ er blevet mere positivt stemt over for Novo Nordisk-aktien.I hvert fald hæver finanshuset kursmålet til 273 kr. fra tidligere 25..

Aktier/åbning: Danske Bank og Novo fører an efter regnskaber

30-10-2014 09:14:46
To af de tunge spillere i eliteindekset C20, Danske Bank og Novo Nordisk, kom torsdag morgen med kvartalsregnskaber inden børsåbning.Og det er da også de to akt..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo Q3: 2014-forventninger skuffer i forhold til konsensus
2
Novo/Sydbank: Levemir-tal gør frygt til skamme
3
Coloplast Q4: Absolut ingen slinger i valsen
4
Aktier/tendens: Novo fører an i regnskabsbølge
5
Danske Q3: Opjusterer efter overraskende stærkt kvartal
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. oktober 2014 23:52:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141028.2 - EUROWEB2 - 2014-10-30 23:52:34 - 2014-10-30 23:52:34 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x